Deletion of Ppard in CD11c+ cells attenuates atherosclerosis in ApoE knockout mice

Danyang Tian1,2, Huiling Hong1, Wenbin Shang1

  • 1School of Biomedical Sciences, Institute of Vascular Medicine, the Chinese University of Hong Kong, Shatin, Hong Kong.

Insights

Peroxisome proliferator-activated receptor delta (PPARδ) in antigen-presenting cells promotes atherosclerosis by activating myeloid dendritic cells and polarizing T cells. Deleting PPARδ in these cells reduces plaque formation and immune cell infiltration.

Area of Science:

  • Immunology
  • Molecular Biology
  • Cardiovascular Research

Background:

  • Peroxisome proliferator-activated receptor delta (PPARδ) is a nuclear receptor involved in lipid metabolism and other cellular functions.
  • The role of antigen-presenting cells (APCs) in atherosclerosis development is complex and not fully understood.
  • PPARδ's function in APCs, particularly dendritic cells (DCs), during atherosclerosis needs further elucidation.

Purpose of the Study:

  • To investigate the role of PPARδ in CD11c+ cells in the development of atherosclerosis.
  • To determine how PPARδ deletion in APCs affects immune cell activation, differentiation, and migration in the context of atherosclerosis.

Main Methods:

  • Conditional deletion of the Ppard gene in CD11c+ cells using the Cre-loxP system in Apoe-/- mice.
  • Induction of atherosclerosis via a high-cholesterol diet.
  • Analysis of atherosclerotic plaque formation, immune cell infiltration, DC activation, and T cell polarization.
  • Assessment of DC migration to lymph nodes and co-stimulatory molecule/cytokine expression in bone marrow-derived DCs.

Main Results:

  • PPARδ deficiency in CD11c+ cells significantly attenuated atherosclerotic plaque formation.
  • Reduced infiltration of myeloid-derived dendritic cells and T lymphocytes was observed.
  • Dendritic cell activation and T cell differentiation into Th1 cells were decreased.
  • DC migration to lymph nodes was diminished, and palmitic acid-induced pro-inflammatory responses in DCs were reduced.

Conclusions:

  • PPARδ activation by fatty acids promotes myeloid DC activation and subsequent T lymphocyte polarization, contributing to atherosclerosis in Apoe-/- mice.
  • PPARδ plays a regulatory role in antigen presentation, orchestrating immune responses during atherosclerosis.
  • Targeting PPARδ in APCs may offer a therapeutic strategy for atherosclerosis.

Related Concept Videos

Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
253
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
710
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
281